Innovation in European healthcare â what can Sweden learn? - LIF

More documents

Recommendations

Info

The French Sécurité Sociale controls the price of innovative drugs – France defines the price of innovative drugs according to the medical benefit provided by the innovative drugs. – The interministerial committee, the CEPS, negotiates the price with the pharmaceutical companies according to the calculated level of improved medical service. – If it is high, the price reference is the one suggested by the phamaceuticals, taking into consideration the price in Germany/UK/Netherlands. – Tendency towards a better harmonisation of the European prices, with increasing pressures from the European Commission. « The French regulated price system for drugs remains a major limitation to the uptake and diffusion of the most innovative – and thefore the most expensive – treatments. » Former R&D director who worked in the pharmaceutical industry for 12 years 90
Hospitals carry out more and more outpatient activities which increase the inpatient drug market for outpatients • Inpatient market represents an increasing share of the total market • 8% growth of the inpatient market since 1999 • In 2009, it represents 20% of the total French pharmaceutical market. This share doubled in 20 years. The 3 segments of the inpatient drugs' market Total: EUR 5.75 billion Retrocession List 25% Not-included in GHS (list of reimbursed drugs) 44% GHS Tariffs 31% The inpatient market is divided into 3 segments: • Drugs included in the different GHS tariffs – High competition, mostly among generics – Stable expenditures • Expensive drugs excluded from GHS (real-cost payments). On the list of Reimbursed Drugs: – Mostly innovative drugs – Increasing share of total drugs expenditures • Drugs that hospitals can provide to outpatients : on the “retrocession” list – Mostly innovative drugs, no competition with generics – Prices fixed by national authorities – The 2005 reform stopped the rapid growth of expenditures: drugs made available in private pharmacies 91
Page 1 and 2:
Innovation in European healthcare -
Page 3 and 4:
Introduction If it was up to the NI
Page 5 and 6:
GDP per capita 2011, thUSD Annual G
Page 7 and 8:
Import Technology uptake Export End
Page 9 and 10:
Venture capital flight away from li
Page 11 and 12:
Issues in Sweden: clinical research
Page 13 and 14:
Issues in Sweden: communication and
Page 15 and 16:
Issues in Sweden: reimbursement for
Page 17 and 18:
Summary - the innovation challenges
Page 19 and 20:
InDex Pharmaceuticals InDex Pharmac
Page 21 and 22:
Addressable Patient Population in E
Page 23 and 24:
What conclusions can be drawn from
Page 25 and 26:
Elekta has established a model for
Page 27 and 28:
The five European countries 27
Page 29 and 30:
German healthcare system • German
Page 31 and 32:
Role of important Government and Of
Page 33 and 34:
Role of important Government and Of
Page 35 and 36:
Germany needs more healthcare for t
Page 37 and 38:
37 DRG was developed in the US in t
Page 39 and 40: The base rate varied during the con
Page 41 and 42: There are public, private for profi
Page 43 and 44: Financing System of the German SHI
Page 45 and 46: Central Changes in the German healt
Page 47 and 48: Innovations in the German Health Ca
Page 49 and 50: Cost of Pharmaceuticals and Medical
Page 51 and 52: Three steps for Integration of New
Page 53 and 54: NUB Process in the German DRG Syste
Page 55 and 56: Innovative drugs in the outpatient
Page 57 and 58: Implementation and use of innovativ
Page 59 and 60: Innovations in the outpatient secto
Page 61 and 62: Implementation and use of innovatio
Page 67 and 68: New possibility of testing potentia
Page 69 and 70: Structural Innovations in the Inpat
Page 71 and 72: Structural Innovations in the Outpa
Page 73 and 74: During the last ten years two centr
Page 75 and 76: France The healthcare system in Fra
Page 77 and 78: Financing of the French health care
Page 79 and 80: The French medical device industry
Page 81 and 82: The French Medical Devices Market:
Page 83 and 84: The average time necessary to get a
Page 85 and 86: Shortening the reimbursement proces
Page 87 and 88: A successful solution to provide ad
Page 89: 2. Pharmaceuticals 89
Page 93 and 94: ATU System: Off label use Exemption
Page 95 and 96: 3. Financial incentives and reimbur
Page 97 and 98: The evaluation of new products by t
Page 99 and 100: Some particularly expensive drugs a
Page 101 and 102: In hospitals, expensive and innovat
Page 103 and 104: The impact of T2A on innovation Act
Page 105 and 106: The Support for Innovative and Cost
Page 107 and 108: Financing innovation through the Pu
Page 109 and 110: 8 clusters specialised in the healt
Page 111 and 112: Medical Devices’ Patenting: less
Page 113 and 114: The example of the SAAT Conectus Al
Page 115 and 116: The UK The healthcare in the UK is
Page 117 and 118: The NHS is underpinned by a set of
Page 119 and 120: Today the PCTs are the main purchas
Page 121 and 122: Prior to the Health and Social Care
Page 123 and 124: Primary Care Trusts (PCTs) have pla
Page 125 and 126: The new national level bodies overs
Page 127 and 128: The NHS, must deliver efficiency sa
Page 129 and 130: PbR was first introduced in 2005/06
Page 131 and 132: The design of HRG4 reflects a signi
Page 133 and 134: PbR is being incrementally reformed
Page 135 and 136: NHS-funded primary care is provided
Page 137 and 138: The Quality of Outcomes Framework (
Page 139 and 140: The Health and Social Care Act (201
Page 141 and 142:
The United Kingdom is a major produ
Page 143 and 144:
£m Healthcare industries are clust
Page 145 and 146:
Several bodies aim to improve the k
Page 147 and 148:
National Institute for Health and C
Page 149 and 150:
Overview of key NICE assessment pro
Page 151 and 152:
NHS National Technology Adoption Ce
Page 153 and 154:
“Innovation” has central place
Page 155 and 156:
Bodies to support innovation in hea
Page 157 and 158:
The UK is a world-leader in life-sc
Page 159 and 160:
There still exists large regional v
Page 161 and 162:
UK rankings and usage as a percenta
Page 163 and 164:
Multiple structural layers within N
Page 165 and 166:
NHS lacks control mechanism for imp
Page 167 and 168:
Short-term budget-cycles often are
Page 169 and 170:
Actions described by respondents du
Page 171 and 172:
Actions described by respondents du
Page 173 and 174:
Actions deriving from the review
Page 175 and 176:
The following measures were suggest
Page 177 and 178:
The planned compliance regime is ge
Page 179 and 180:
Actions to incentivise innovation t
Page 181 and 182:
NICE’s HTA process: NICE’s stan
Page 183 and 184:
The implementation of NICE guidelin
Page 185 and 186:
Implementation: A recommended proce
Page 187 and 188:
The NHS Technology Adoption Centre
Page 189 and 190:
The Government has invested a recor
Page 191 and 192:
The Government’s funding has also
Page 193 and 194:
Case 2: AstraZeneca and NIHR Cancer
Page 195 and 196:
The NIHR has also established Healt
Page 197 and 198:
As part of the Government’s Life
Page 199 and 200:
All applications for the Biomedical
Page 201 and 202:
NOCRI has worked together with MRC
Page 203 and 204:
Academic Health Science Centres (AH
Page 205 and 206:
What can Sweden learn from the UK?
Page 207 and 208:
Facts - the proportions of Danish h
Page 209 and 210:
The Danish healthcare system is pri
Page 211 and 212:
Public-private investments in R & D
Page 213 and 214:
The Danish healthcare industry is a
Page 215 and 216:
Public investments in the future st
Page 217 and 218:
The public renewal fund is meant to
Page 219 and 220:
With the responsibility for adminis
Page 221 and 222:
Organisational chart - the capital
Page 223 and 224:
The Innovation environments invest
Page 225 and 226:
Overall the innovation environments
Page 227 and 228:
Sara established a successful busin
Page 229 and 230:
Infrastructure for Innovation - The
Page 231 and 232:
The networks consist of 22 innovati
Page 233 and 234:
The overall Danish Innovation infra
Page 235 and 236:
The new market maturing-fund will h
Page 237 and 238:
The new Danish Innovation strategy
Page 239 and 240:
Subsidy for new outpatient medicame
Page 241 and 242:
The evaluation and assessment of ne
Page 243 and 244:
Cost reduction in expensive hospita
Page 245 and 246:
The public procurement of Medtech -
Page 247 and 248:
Innovative public procurement of Me
Page 249 and 250:
What can Sweden learn from Denmark?
Page 251 and 252:
The Netherlands are spending more o
Page 253 and 254:
Health insurers are allowed to make
Page 255 and 256:
Financial flows in the Dutch health
Page 257 and 258:
Impact of the reform on providers
Page 259 and 260:
Impact of the reform on patients/in
Page 261 and 262:
Impact of the reform The Dutch heal
Page 263 and 264:
Innovations in the Dutch healthcare
Page 265 and 266:
The reimbursement system should all
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Summary and conclusions 277
Page 279 and 280:
There is a correlation between a co
Page 281 and 282:
Conclusions - what can Sweden learn
Page 283 and 284:
Two general recommendations and one
Page 285:
www.vascoadvisers.com Supported by
show all

Innovation in European healthcare â what can Sweden learn? - LIF

Create successful ePaper yourself

Delete template?

Save as template?

Innovation in European healthcare â what can Sweden learn? - LIF